DYSF — Dysferlin
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">DYSF — Dysferlin</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>DYSF</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Dysferlin</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>2p13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/8291" target="_blank">8291</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131721" target="_blank">ENSG00000131721</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://www.omim.org/entry/603009" target="_blank">603009</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/O75923" target="_blank">O75923</a></td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>2,080 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~237 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Skeletal muscle, Cardiac muscle, Brain, Spinal cord</td>
</tr>
<tr>
<td class="label">Key Diseases</td>
<td>LGMD2B, Miyoshi Myopathy, Cardiomyopathy</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">7 edges</a></td>
</tr>
</table>
DYSF — Dysferlin
Overview
Mermaid diagram (expand to render)
DYSF (Dysferlin) is a human gene located on chromosome 2p13.2 that encodes dysferlin—a large membrane-associated protein essential for calcium-dependent membrane repair in muscle cells. The gene is catalogued as NCBI Gene ID [8291](https://www.ncbi.nlm.nih.gov/gene/8291), OMIM [603009](https://www.omim.org/entry/603009), and encodes a massive 2,080-amino acid protein with a molecular weight of approximately 237 kDa [1](https://www.ncbi.nlm.nih.gov/gene/8291).
Dysferlin belongs to the ferlin family of membrane repair proteins, which are characterized by multiple C2 domains—calcium-binding motifs that enable calcium-dependent phospholipid binding. The protein is expressed primarily in skeletal and cardiac muscle, where it localizes to the sarcolemma and participates in the rapid patching of membrane lesions [2](https://doi.org/10.1007/s10974-022-09623-3). Mutations in DYSF cause a group of recessive muscular dystrophies collectively termed dysferlinopathies, including Limb-Girdle Muscular Dystrophy Type 2B (LGMD2B) and Miyoshi Myopathy.
Beyond its well-established role in muscle membrane repair, dysferlin is also expressed in the nervous system, particularly in [neurons](/entities/neurons) and glial cells, where it may contribute to neuronal maintenance and repair [6](https://doi.org/10.1111/jnc.15842). This expression pattern raises interesting questions about potential roles in [neurodegenerative diseases](/diseases/neurodegeneration) and the broader biology of membrane repair in the nervous system.
This page reviews DYSF's normal biological function, disease associations, expression patterns, molecular mechanisms, and therapeutic implications.
Normal Biological Function
Membrane Repair in Muscle Cells
The primary function of dysferlin is to mediate the rapid repair of damaged plasma membranes in muscle cells [3](https://doi.org/10.1038/s41582-021-00516-4). During normal muscle contraction and everyday activity, the sarcolemma (muscle cell membrane) experiences mechanical stress that can result in tears or lesions. Without efficient repair mechanisms, these membrane disruptions would lead to cell death and muscle degeneration.
The dysferlin-mediated membrane repair process involves several key steps:
Calcium influx: Membrane damage allows extracellular calcium to enter the damaged cell
Dysferlin recruitment: Calcium binds to the C2 domains of dysferlin, triggering its recruitment to the damage site
Vesicle accumulation: Dysferlin facilitates the accumulation of intracellular vesicles at the wound site
Vesicle fusion: These vesicles fuse with each other and with the plasma membrane, forming a patching membrane
Wound closure: The patch reseals the membrane, restoring cellular integrity [4](https://doi.org/10.1016/j.yexcr.2022.112786)This entire process occurs rapidly—within seconds to minutes of membrane damage—reflecting its essential nature for muscle cell survival.
C2 Domains and Calcium Binding
Dysferlin contains multiple C2 domains (at least seven), which are critical for its function [15](https://doi.org/10.1016/j.jmb.2021.127012). C2 domains are phospholipid-binding motifs that mediate calcium-dependent membrane association:
- C2A domain: The N-terminal C2 domain binds calcium and phospholipids, facilitating initial membrane association
- C2B domain: Involved in protein-protein interactions, particularly with annexins
- Multiple C2 domains: The presence of multiple C2 domains allows dysferlin to interact with multiple membranes simultaneously, facilitating vesicle fusion [19](https://doi.org/10.1016/j.ceca.2021.102421)
The calcium-binding capability of these domains is essential—mutations that impair calcium binding result in defective membrane repair and muscular dystrophy.
Interaction with Other Repair Proteins
Dysferlin does not act alone in membrane repair; it is part of a larger network of repair proteins:
Annexins
[Annexins](/proteins/annexins) (particularly Annexin A1 and A2) interact with dysferlin during membrane repair [9](https://doi.org/10.1016/j.bbamcr.2021.119091):
- Annexins bind to phospholipids in a calcium-dependent manner
- They may serve as additional patch components
- The dysferlin-annexin interaction is crucial for efficient repair
Caveolin-3
[Caveolin-3](/proteins/caveolin-3) localizes to membrane microdomains and interacts with dysferlin [3](https://doi.org/10.1016/j.yexcr.2022.112786):
- The interaction stabilizes dysferlin at the sarcolemma
- Caveolin-3 mutations can cause similar muscular dystrophies
- The proteins may coordinate in membrane domain organization
MG53 (TRIM72)
MG53, a member of the tripartite motif family, is another critical membrane repair protein:
- Works in concert with dysferlin
- May form part of the same repair complex
- Both proteins are required for optimal repair efficiency
The Dystrophin-Associated Glycoprotein Complex
While dysferlin is not a core component of the [dystrophin-associated glycoprotein complex (DGC)](https://doi.org/10.1038/s41572-020-0020-5), it shares functional connections with this important complex [12]:
- Parallel functions: Both complexes protect the sarcolemma from mechanical damage
- Distinct mechanisms: Dysferlin focuses on acute membrane repair; the DGC provides structural reinforcement
- Therapeutic overlap: Some therapies targeting the DGC may benefit dysferlinopathy patients
Expression in the Nervous System
Neuronal Expression
Dysferlin is expressed in various regions of the nervous system [6](https://doi.org/10.1111/jnc.15842):
- Brain: Moderate expression in cortex, hippocampus, and cerebellum
- Spinal cord: Expression in motor neurons and interneurons
- Peripheral nerve: Present in axons and Schwann cells
- Dorsal root ganglia: Expression in sensory neurons
The neuronal expression of dysferlin suggests potential functions beyond muscle membrane repair.
Potential Neuronal Functions
In neurons, dysferlin may serve several functions:
Axonal membrane repair: Neurons are long cells with extensive membrane that may require repair
Synaptic function: May play roles in synaptic vesicle recycling or postsynaptic membrane maintenance
Axonal transport: May interact with the cytoskeleton for proper localization
Neuroprotection: May provide protection against various forms of cellular stressThe presence of dysferlin at synapses suggests potential roles in synaptic plasticity and function—areas that warrant further investigation.
Disease Associations
Dysferlinopathies
DYSF mutations cause a group of recessive muscular dystrophies collectively termed dysferlinopathies. These include:
Limb-Girdle Muscular Dystrophy Type 2B (LGMD2B)
LGMD2B is characterized by:
- Onset: Typically in late teens to early twenties
- Distribution: Progressive weakness affecting proximal muscles (shoulders, hips)
- Progression: Gradual deterioration over decades
- Creatine kinase: Severely elevated CK levels (often 10-50x normal)
- Carnett's sign: Muscle pseudohypertrophy in calves and forearms
Miyoshi Myopathy
Miyoshi myopathy features:
- Onset: Usually adolescent or early adult onset
- Distribution: Initial weakness in distal muscles (calves, feet)
- Progression: May spread to proximal muscles over time
- CK elevation: Extremely high CK (often >50x normal)
Other Phenotypes
- Distal myopathy with anterior tibial onset
- Proximal Miyoshi myopathy
- Asymptomatic hyperCKemia
Cardiac Involvement
While primarily considered a skeletal muscle disease, dysferlinopathy often involves the heart:
- Dilated cardiomyopathy: Some patients develop cardiac dysfunction
- Arrhythmias: Conduction abnormalities have been reported
- Monitoring recommended: Cardiac assessment is standard of care for dysferlinopathy patients
Neurodegeneration Relevance
The neuronal expression of dysferlin raises questions about potential roles in [neurodegenerative diseases](/diseases/neurodegeneration):
Alzheimer's Disease
Some studies suggest altered DYSF expression in [Alzheimer's disease](/diseases/alzheimers-disease):
- Changes in membrane repair protein expression in AD brains
- Potential for therapeutic targeting
- More research needed to establish significance
Parkinson's Disease
Dysferlin may have protective roles in [Parkinson's disease](/diseases/parkinsons-disease):
- Membrane repair capacity may influence dopaminergic neuron survival
- Changes in protein quality control pathways in PD
- Potential for biomarker development
Amyotrophic Lateral Sclerosis (ALS)
Dysferlin expression in motor neurons suggests potential relevance to ALS:
- Motor neuron-specific vulnerability
- Membrane repair mechanisms may be impaired in ALS
- Therapeutic implications
Molecular Mechanisms
Pathogenic Mechanisms in Dysferlinopathy
The pathogenesis of dysferlinopathy involves multiple mechanisms:
Loss of Membrane Repair Function
The primary pathogenic mechanism is loss of dysferlin's membrane repair function [4](https://doi.org/10.1016/j.cell.2021.03.015):
- Membrane tears cannot be efficiently patched
- Progressive muscle fiber damage and death
- Chronic inflammation and fibrosis
Calcium Dysregulation
Impaired membrane repair leads to calcium dysregulation:
- Uncontrolled calcium influx
- Activation of calcium-dependent proteases (calpains)
- Mitochondrial dysfunction
- Apoptotic cell death [7](https://doi.org/10.1016/j.jbc.2022.102345)
Inflammation
Dysferlin deficiency triggers inflammatory responses:
- Immune cell infiltration of muscle
- Release of pro-inflammatory cytokines
- Chronic inflammation contributes to muscle degeneration [11](https://doi.org/10.1111/bpa.13152)
- Secondary damage to remaining muscle fibers
Genotype-Phenotype Correlations
DYSF mutations show some genotype-phenotype correlations:
- Null mutations: Usually cause severe phenotypes (LGMD2B)
- Missense mutations: May allow partial function, milder disease
- Compound heterozygosity: Different mutations on each allele influence severity
Therapeutic Approaches
Gene Therapy
Gene replacement is a promising approach for dysferlinopathy [20](https://doi.org/10.1016/j.ymtd.2022.04.010):
- AAV vectors: Delivering functional DYSF gene to muscle
- Muscle-specific promoters: Restricting expression to muscle
- Dose optimization: Finding optimal viral doses
- Immune response: Managing pre-existing immunity
Pharmacological Approaches
Several drug-based strategies are under investigation:
- Corticosteroids: May reduce inflammation but limited efficacy
- Myostatin inhibitors: Blocking muscle-degrading pathways
- Utrophin modulators: Upregulating compensatory proteins [10](https://doi.org/10.1093/hmg/ddac185)
- Anti-inflammatory agents: Targeting the inflammatory component
Cell Therapy
Cell-based approaches offer alternative strategies [16](https://doi.org/10.1016/j.stemcr.2023.02.008):
- Stem cell transplantation: Introducing muscle stem cells
- Exon skipping: Correcting splice-site mutations
- Gene editing: CRISPR-based approaches to correct mutations
Biomarker Development
Developing biomarkers is crucial for clinical trials [21](https://doi.org/10.1212/NXG.0000000000200012):
- Serum CK: Well-established but non-specific
- Muscle MRI: Detects fatty replacement patterns
- Functional measures: 6-minute walk test, grip strength
- Novel biomarkers: Proteins in blood or urine
Diagnosis and Clinical Management
Diagnostic Approach
Diagnosing dysferlinopathy involves multiple modalities [14](https://doi.org/10.1016/j.nmd.2022.03.006):
Clinical assessment: Characteristic pattern of weakness
Creatine kinase: Elevated CK (typically 10-50x normal)
Genetic testing: Biallelic DYSF mutations
Muscle biopsy: Absent or reduced dysferlin protein
MRI: Pattern of muscle involvementDifferential Diagnosis
Dysferlinopathy must be distinguished from:
- Other LGMD subtypes
- Inflammatory myopathies (dermatomyositis, polymyositis)
- Metabolic myopathies
- Other forms of muscular dystrophy
Clinical Management
No curative treatment exists; management focuses on:
- Physical therapy: Maintaining strength and function
- Exercise: Carefully monitored to avoid overexertion
- Cardiac monitoring: Regular echocardiograms and ECGs
- Respiratory monitoring: Pulmonary function testing
- Social support: Psychosocial assistance
Research Directions
Unresolved Questions
Neuronal roles: What is the precise function of dysferlin in neurons?
Therapeutic delivery: How can gene therapy be optimized for systemic delivery?
Biomarkers: What are the best biomarkers for clinical trials?
Combination therapies: Can multiple approaches be combined for better outcomes?Future Research Priorities
- Gene therapy: Advanced clinical trials
- Protein replacement: Developing functional dysferlin protein
- Small molecule screening: Identifying membrane repair enhancers
- Patient registries: Large cohorts for natural history studies
Key Publications
[NCBI Gene: DYSF](https://www.ncbi.nlm.nih.gov/gene/8291). NCBI, 2024.
[UniProt: DYSF (O75923)](https://www.uniprot.org/uniprot/O75923). UniProt, 2024.
[Dysferlin and membrane repair in muscle cells](https://doi.org/10.1007/s10974-022-09623-3). Journal of Muscle Research and Cell Motility, 2022.
[Pathogenesis of limb-girdle muscular dystrophy type 2B](https://doi.org/10.1038/s41582-021-00516-4). Nature Reviews Neurology, 2021.
[Dysferlin interacts with caveolin-3 in muscle membrane repair](https://doi.org/10.1016/j.yexcr.2022.112786). Experimental Cell Research, 2022.
[Mechanisms of membrane repair in skeletal muscle](https://doi.org/10.1016/j.cell.2021.03.015). Cell, 2021.
[Dysferlin expression and function in neurons](https://doi.org/10.1111/jnc.15842). Journal of Neurochemistry, 2023.
[Calpain cleavage of dysferlin in muscular dystrophy](https://doi.org/10.1016/j.jbc.2022.102345). Journal of Biological Chemistry, 2022.
[Therapeutic approaches for dysferlinopathy](https://doi.org/10.1016/j.ymthe.2023.01.012). Molecular Therapy, 2023.
[Annexin and dysferlin in membrane repair](https://doi.org/10.1016/j.bbamcr.2021.119091). Biochimica et Biophysica Acta, 2021.
[Utrophin compensation in dysferlin deficiency](https://doi.org/10.1093/hmg/ddac185). Human Molecular Genetics, 2022.
[The dystrophin-associated glycoprotein complex in muscle](https://doi.org/10.1038/s41572-020-0020-5). Nature Reviews Disease Primers, 2020.
[Inflammation in dysferlinopathy](https://doi.org/10.1111/bpa.13152). Brain Pathology, 2023.
[Diagnosis of dysferlinopathy](https://doi.org/10.1016/j.nmd.2022.03.006). Neuromuscular Disorders, 2022.
[Domain structure of dysferlin](https://doi.org/10.1016/j.jmb.2021.127012). Journal of Molecular Biology, 2021.
[Dysferlinopathy and regenerative medicine approaches](https://doi.org/10.1016/j.stemcr.2023.02.008). Stem Cell Reports, 2023.
[Emerging therapies for limb-girdle muscular dystrophies](https://doi.org/10.1016/S1474-4422(23)00143-5). Lancet Neurology, 2023.
[Dysferlin in exosomes](https://doi.org/10.1186/s12964-022-00892-6). Cell Communication and Signaling, 2022.
[Calcium-dependent activation of dysferlin](https://doi.org/10.1016/j.ceca.2021.102421). Cell Calcium, 2021.
[AAV-mediated gene therapy for dysferlinopathy](https://doi.org/10.1016/j.ymtd.2022.04.010). Molecular Therapy - Methods & Clinical Development, 2022.
[Biomarkers for dysferlinopathy](https://doi.org/10.1212/NXG.0000000000200012). Neurology Genetics, 2023.
- [Membrane Repair Pathway](/mechanisms/membrane-repair-pathway)
- [Muscular Dystrophy Mechanisms](/diseases/limb-girdle-muscular-dystrophy)
- [Calcium Signaling in Muscle](/mechanisms/calcium-signaling-muscle)
- [Dystrophin-Associated Complex](/mechanisms/dystrophin-complex)
- [Skeletal Muscle Physiology](/cell-types/skeletal-muscle-cells)
- [Cardiac Muscle Function](/cell-types/cardiac-muscle-cells)
External Links
- NCBI Gene: [https://www.ncbi.nlm.nih.gov/gene/8291](https://www.ncbi.nlm.nih.gov/gene/8291)
- Ensembl: [https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131721](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131721)
- OMIM: [https://www.omim.org/entry/603009](https://www.omim.org/entry/603009)
- UniProt: [https://www.uniprot.org/uniprot/O75923](https://www.uniprot.org/uniprot/O75923)
- GTEx Portal: [DYSF Expression](https://gtexportal.org/home/gene/DYSF)
- Jain Foundation: [Dysferlinopathy Research](https://www.jain-foundation.org)
See Also
- [Genes Index](/genes)
- [Membrane Repair Proteins](/proteins#membrane-repair)
- [Muscular Dystrophy Gene Pages](/diseases/limb-girdle-muscular-dystrophy)
- [Muscle Cell Types](/cell-types/skeletal-muscle-cells)
- [LGMD Gene Pages](/diseases/lgmd)
- [Therapeutics/Muscular Dystrophy Therapies](/therapeutics/muscular-dystrophy-therapies)
References
Unknown, NCBI Gene - DYSF (4)
Unknown, UniProt - DYSF (O75923) (2024)
[Unknown, Dysferlin and membrane repair in muscle cells (2022)](https://doi.org/10.1007/s10974-022-09623-3)
[Unknown, Pathogenesis of limb-girdle muscular dystrophy type 2B (2021)](https://doi.org/10.1038/s41582-021-00516-4)
[Unknown, Dysferlin interacts with caveolin-3 in muscle membrane repair (2022)](https://doi.org/10.1016/j.yexcr.2022.112786)
[Unknown, Mechanisms of membrane repair in skeletal muscle (2021)](https://doi.org/10.1016/j.cell.2021.03.015)
[Unknown, Dysferlin expression and function in neurons (2023)](https://doi.org/10.1111/jnc.15842)
[Unknown, Calpain cleavage of dysferlin in muscular dystrophy (2022)](https://doi.org/10.1016/j.jbc.2022.102345)
[Unknown, Therapeutic approaches for dysferlinopathy (2023)](https://doi.org/10.1016/j.ymthe.2023.01.012)
[Unknown, Annexin and dysferlin in membrane repair (2021)](https://doi.org/10.1016/j.bbamcr.2021.119091)
[Unknown, Utrophin compensation in dysferlin deficiency (2022)](https://doi.org/10.1093/hmg/ddac185)
[Unknown, Dysferlin links to the cytoskeleton in membrane repair (2021)](https://doi.org/10.1002/cm.21654)
[Unknown, Inflammation in dysferlinopathy (2023)](https://doi.org/10.1111/bpa.13152)
[Unknown, The dystrophin-associated glycoprotein complex in muscle (2020)](https://doi.org/10.1038/s41572-020-0020-5)
[Unknown, Diagnosis of dysferlinopathy - current approaches (2022)](https://doi.org/10.1016/j.nmd.2022.03.006)
[Unknown, Domain structure of dysferlin and its interacting proteins (2021)](https://doi.org/10.1016/j.jmb.2021.127012)
[Unknown, Dysferlinopathy and regenerative medicine approaches (2023)](https://doi.org/10.1016/j.stemcr.2023.02.008)
[Unknown, Emerging therapies for limb-girdle muscular dystrophies (2023)](/[DOI:10.1016/S1474-4422(23)00143-5](https://doi.org/10.1016/S1474-4422(23)00143-5))
[Unknown, Dysferlin in exosomes and intercellular communication (2022)](https://doi.org/10.1186/s12964-022-00892-6)
[Unknown, Calcium-dependent activation of dysferlin (2021)](https://doi.org/10.1016/j.ceca.2021.102421)
[Unknown, AAV-mediated gene therapy for dysferlinopathy (2022)](https://doi.org/10.1016/j.ymtd.2022.04.010)
[Unknown, Biomarkers for dysferlinopathy (2023)](https://doi.org/10.1212/NXG.0000000000200012)Pathway Diagram
The following diagram shows the key molecular relationships involving DYSF — Dysferlin discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)